[1]夏新舍,王勇,叶红强,等.腮腺癌术后高危复发区放疗的不同治疗计划剂量学比较[J].国际放射医学核医学杂志,2010,34(4):250-255.[doi:10.3760/cma.j.issn.1673-4114.2010.04.016]
　XIA Xin-she,WANG Yong,YE Hong-qiang,et al.The dosimetric comparison of different treatment planning for parotid tumors postoperative radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(4):250-255.[doi:10.3760/cma.j.issn.1673-4114.2010.04.016]
点击复制

腮腺癌术后高危复发区放疗的不同治疗计划剂量学比较(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
34
期数:
2010年第4期
页码:
250-255
栏目:
临床放射医学
出版日期:
1900-01-01

文章信息/Info

Title:
The dosimetric comparison of different treatment planning for parotid tumors postoperative radiotherapy
作者:
夏新舍;  王勇;  叶红强;  黑忠林;  郭艳红;  王艳阳;  闫刚;  詹文华;  马建萍
750004, 银川, 宁夏医科大学附属医院肿瘤放疗科
Author(s):
XIA Xin-she;  WANG Yong;  YE Hong-qiang;  HEI Zhong-lin;  GUO Yan-hong;  WANG Yan-yang;  YAN Gang;  ZHAN Wen-hua;  MA Jian-ping
Department of Radiation Oncology, Affliated Hospital of Ningxia Medical University, Yinchuan 750004, China
关键词:
腮腺肿瘤; 近距离放射疗法; 适形放射疗法; 调强放射疗法; 放射治疗计划; 计算机辅助
Keywords:
Parotid neoplasms; Brachytherapy; Conformal radiotherapy; intensity modulated radiotherapy; Radiotherapy planning; compute-assisted
DOI:
10.3760/cma.j.issn.1673-4114.2010.04.016
摘要:
目的 探讨腮腺癌术后高危复发区用何种照射方法可以更有效的使靶区剂量均匀及更好的保护危及器官。方法 对8例腮腺癌术后患者设计治疗计划,处方剂量为95%计划靶区(PTV)60 Gy/30次。对常规放疗、二维适形放疗(2D-CRT)、三维适形放疗(3D-CRT)和调强放疗(IMRT)等放射治疗技术的腮腺癌术后靶区进行放疗计划设计,分析比较各种治疗计划靶区适形度和在保护危及器官等方面的优劣。结果 在2D-CRT时,以计算点深度取3.5 cm,电子线能量采取12 MeV及X射线/电子射线(X/E)剂量比为1:2时靶区的适形度和均匀度较好,危及器官的受量较低。与2D-CRT比较,常规放疗照射野能够较好地包括CT断层图像上勾画的靶区。与2D-CRT及3D-CRT相比,IMRT计划有最好的靶区适形度及均匀度,同时对危及器官有较好的保护作用。结论 X射线与电子线混合线束照射时,剂量计算点深度取3.5 cm左右、电子线能量采取12 MeV及X/E剂量比为1:2时,靶区的适形度和均匀度较好,对正常组织的保护较好,但具体患者最好用计划系统来选择以上指标。常规放疗按解剖标志确定的照射野能够较好地包括三维靶区。IMRT计划的靶区适形度及均匀度最好,并且危及器官受量较低,在腮腺癌术后放射治疗中IMRT技术是值得推广并普及的放射治疗技术。
Abstract:
Objective To evaluate what is the optimum radiation technique for parotid tumors postoperative radiotherapy to achieve dose uniformity and protection organs at risk. Methods Dose distribution of different plans were calculated and compared for 8 patients treated in our hospital. In each case, the dose of 95% PTV was prescribed to 60 Gy/30 fractions. The conventional radiotherapy, 2-dimensional conformal radiotherapy(2D-CRT), 3-dimensional conformal radiotherapy(3D-CRT) and intensity modulated radiotherapy (IMRT) planning are designed. The dose conformity, uniformity index and dose sparing of organs at risk of all plans were compared. Results The 2D-CRT plan of dose calculated depth 3.5with lower sparing dose of organs at risk. Compared to the 2D-CRT, conventional radiotheraphy plan could cover target drawn in CT slice. The IMRT plans were more preferable in achieving better dose conformity with lower sparing dose of majority organs at risk than that of the 2D-CRT and 3D-CRT. Conclusions The 2D photon and 12 MeV electron beams may be suitable to get a better coverage and uniformity for parotid tumors postoperative radiotherapy. In practice, we recommended to use treatment planning system to select the optimum plan for any patient. The conventional radiotheraphy field according to anatomic marker could get a better target coverage. The IMRT plan have best conformity and uniformity with a lower sparing dose of organs at risk. The IMRT technique should be used extensively for parotid tumors postoperative radiotherapy in future.

参考文献/References:

[1] 李素艳.涎腺肿瘤//殷蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学.4版.北京:中国协和医科大学出版社,2008:498-509.
[2] 殷蔚伯,余耘,陈波,等.2006年全国放疗人员及设备调查报告——纪念中华放射肿瘤学会成立20周年.中华放射肿瘤学杂志,2007,16(1):1-5.
[3] International Commission on Radiation Units and Measurements.ICRU Report 62:Prescribing,recording and reporting photon beam therapy(Supplement to ICRU report 50).Edthesda,MD:ICRU,1999:21-21.
[4] Bragg CM,Conway J,Robinson MH.The role of intensity-modulated radiotherapy in the treatment of parotid tumors.Int J Radiat Oncol Biol Phys,2002,52(3):729-738.
[5] Liu HH,Wang X,Dong L,et al.Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for nonsmall cell lung cancer.Int J Radiat Oncol Biol Phys,2004,58(4):1268-1279.
[6] 肖光莉.唾液腺肿瘤//刘泰福.现代放射肿瘤学.上海:上海医科大学出版社,2001:219-223.
[7] Knöös T,Kristensen I,Nilssion P.Volumetric and dosimetric evaluation of radiation treatment plans:radiation conformity index.Int J Radiat Oncol Biol Phys,1998,42(5):1169-1176.
[8] 邹中华,史建平,吴锦昌,等.腮腺癌术后不同放疗计划剂量学的比较.中国癌症杂志,2010,20(3):212-217.

相似文献/References:

[1]田琦,张丽花,蒋宁一.甲状腺癌131I治疗后合并骨髓增生异常综合征一例[J].国际放射医学核医学杂志,2016,40(3):235.[doi:10.3760/cma.j.issn.1673-4114.2016.03.014]
[2]霍小东,王慧星,阎卫亮,等.血管内皮抑制素对125I近距离照射裸鼠肺癌移植瘤的增敏效应研究[J].国际放射医学核医学杂志,2016,40(5):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
　Huo Xiaodong,Wang Huixing,Yan Weiliang,et al.Sensitization effect of endostatin for 125I brachytherapy on transplanted tumor in nude mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
[3]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[4]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[5]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[6]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[7]侯朝华,霍彬,宋杨.组织间近距离放射性粒子植入治疗肿瘤的进展[J].国际放射医学核医学杂志,2015,39(4):348.[doi:10.3760/cma.j.issn.1673-4114.2015.04.016]
　Hou Zhaohua,HuoBin,SongYang.Organizational close radioactive seed implantation therapy in treating tumor progression[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):348.[doi:10.3760/cma.j.issn.1673-4114.2015.04.016]
[8]俞秀华,黄炜坤,林玉梅.131I治疗Graves病合并肝损害的临床观察[J].国际放射医学核医学杂志,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
　Yu Xiuhua,Huang Weikun,Lin Yumei.Clinical observation of 131I therapy in Graves disease patients with hepatic dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
[9]张俊涛.晚期肺癌125I粒子植入治疗近期疗效观察[J].国际放射医学核医学杂志,2014,38(2):94.[doi:10.3760/cma.j.issn.1673-4114.2014.02.006]
　Zhang Juntao.Short-term efficacy of 125I seeds implantation in the treatment of advanced lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):94.[doi:10.3760/cma.j.issn.1673-4114.2014.02.006]
[10]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
　Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]

备注/Memo

备注/Memo:
收稿日期:2010-04-09。
通讯作者:夏新舍,E-mail:bydfyxxs@163.com
更新日期/Last Update: 1900-01-01